Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRK-700 + midazolam
- Development stage
- Discontinued
- Lead developer
- Toray Industries
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TRK-700 + midazolam is a drug combination primarily utilized in clinical pharmacology studies to evaluate the drug-drug interaction potential of TRK-700, a novel G protein-coupled bile acid receptor 1 (GPBAR1/TGR5) agonist developed by Toray Industries. TRK-700 was investigated for the treatment of pruritus associated with cholestatic liver diseases, such as primary biliary cholangitis (PBC). Midazolam, a short-acting benzodiazepine and a sensitive substrate for the cytochrome P450 3A4 (CYP3A4) enzyme, serves as a probe to determine whether TRK-700 acts as an inhibitor or inducer of this metabolic pathway. The co-administration is not a therapeutic product but a specific regimen used in Phase 1 trials to characterize the metabolic profile and safety of TRK-700 when administered alongside other medications.
- Other names
- TRK-700 and midazolamTRK700 and midazolamTRK 700 and midazolam
02
Targets
CYP3A4 (Cytochrome P450 3A4)GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on TRK-700 + midazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRK-700 + midazolam.